Last updated: 16 February 2024 at 5:45pm EST

Charles O'Keeffe Net Worth




The estimated Net Worth of Charles B O'keeffe is at least $14.9 Million dollars as of 15 February 2024. Mr. keeffe owns over 4,000 units of Catalyst Pharmaceuticals Inc stock worth over $13,344,189 and over the last 18 years he sold CPRX stock worth over $1,411,279. In addition, he makes $169,564 as Lead Independent Director at Catalyst Pharmaceuticals Inc.

Mr. Keeffe CPRX stock SEC Form 4 insiders trading

Charles has made over 53 trades of the Catalyst Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of CPRX stock worth $77,840 on 15 February 2024.

The largest trade he's ever made was exercising 105,000 units of Catalyst Pharmaceuticals Inc stock on 2 October 2014 worth over $94,500. On average, Charles trades about 11,729 units every 81 days since 2007. As of 15 February 2024 he still owns at least 685,724 units of Catalyst Pharmaceuticals Inc stock.

You can see the complete history of Mr. keeffe stock trades at the bottom of the page.





Charles O'Keeffe biography

Charles B. O'Keeffe is Lead Independent Director of Catalyst Pharmaceutical Partners, Inc. Mr. O’Keeffe also served as a consultant to us from December 2004 until June 2011. Mr. O’Keeffe is a Professor in the Departments of Pharmacology, Epidemiology and Community Health at Virginia Commonwealth University (“VCU”), and has served in such capacity since January 1, 2004. Mr. O’Keeffe joined VCU after retiring as President and Chief Executive Officer of Reckitt Benckiser Pharmaceuticals, Inc., a position Mr. O’Keeffe held from 1991 until 2003. As President of Drug Abuse Rehabilitation Services (from 1970 until 1971), he developed the first child-resistant, abuse-resistant vehicle for dispensing methadone. He served as president of Washington Reference Laboratories from 1972 until 1975, which provided toxicology services to the Department of Defense during the Vietnam War. He has served in the White House (from 1970 until 1973 and from 1976 until 1980) for three presidents—as advisor, special assistant for international health and deputy director for international affairs in the Office of Drug Abuse Policy—and has served on U.S. delegations to the World Health Assembly and the U.N. Commission on Narcotic Drugs. The Board believes the characteristics that qualify Mr. O’Keeffe to serve as a member of our Board include his business leadership experience and his experience in the pharmaceutical industry.

What is the salary of Charles Keeffe?

As the Lead Independent Director of Catalyst Pharmaceuticals Inc, the total compensation of Charles Keeffe at Catalyst Pharmaceuticals Inc is $169,564. There are 10 executives at Catalyst Pharmaceuticals Inc getting paid more, with Patrick McEnany having the highest compensation of $3,371,560.



How old is Charles Keeffe?

Charles Keeffe is 80, he's been the Lead Independent Director of Catalyst Pharmaceuticals Inc since 2011. There are no older and 16 younger executives at Catalyst Pharmaceuticals Inc.

What's Charles Keeffe's mailing address?

Charles's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 801, , CORAL GABLES, FL, 33134.

Insiders trading at Catalyst Pharmaceuticals Inc

Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over $35,595,986 worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth $7,307,159 . The most active insiders traders include Pharmaceutical Inc Biomarin, Patrick J Mcenany, and Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $1,097,019. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth $60,150.



What does Catalyst Pharmaceuticals Inc do?

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso



What does Catalyst Pharmaceuticals Inc's logo look like?

Catalyst Pharmaceuticals Inc logo

Complete history of Mr. keeffe stock trades at Catalyst Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
15 Feb 2024 Charles B O'keeffe
Director
Option 4,000 $13.89 $55,560
15 Feb 2024
685,724
2 Jan 2024 Charles B O'keeffe
Director
Option 60,000 $1.13 $67,800
2 Jan 2024
681,724
27 Dec 2023 Charles B O'keeffe
Director
Option 1,333 $17.29 $23,048
27 Dec 2023
621,724
15 Feb 2023 Charles B O'keeffe
Director
Option 4,000 $15.36 $61,440
15 Feb 2023
620,391
24 Jan 2023 Charles B O'keeffe
Director
Option 50,000 $0.79 $39,500
24 Jan 2023
616,391
6 Dec 2022 Charles B O'keeffe
Director
Option 1,334 $16.46 $21,958
6 Dec 2022
566,391
15 Nov 2022 Charles B O'keeffe
Director
Sale 87,985 $16.04 $1,411,279
15 Nov 2022
565,057
18 Aug 2022 Charles B O'keeffe
Director
Option 40,000 $2.53 $101,200
18 Aug 2022
653,042
3 Dec 2021 Charles B O'keeffe
Director
Option 1,333 $6.86 $9,144
3 Dec 2021
613,042
16 Aug 2021 Charles B O'keeffe
Director
Option 50,000 $3.12 $156,000
16 Aug 2021
611,709
22 Dec 2020 Charles B O'keeffe
Director
Option 1,333 $3.42 $4,559
22 Dec 2020
561,709
30 Sep 2020 Charles B O'keeffe
Director
Buy 7,000 $2.99 $20,930
30 Sep 2020
560,376
11 Oct 2019 Charles B O'keeffe
Director
Buy 10,000 $4.70 $47,000
11 Oct 2019
553,376
14 Dec 2018 Charles B O'keeffe
Director
Buy 20,000 $2.50 $50,000
14 Dec 2018
543,376
7 Jun 2018 Charles B O'keeffe
Director
Buy 1,000 $3.35 $3,350
7 Jun 2018
523,376
7 Jun 2018 Charles B O'keeffe
Director
Buy 4,000 $3.31 $13,240
7 Jun 2018
522,376
1 Jun 2018 Charles B O'keeffe
Director
Buy 5,000 $3.74 $18,700
1 Jun 2018
518,376
16 Nov 2017 Charles B O'keeffe
Director
Option 50,000 $0.47 $23,500
16 Nov 2017
513,376
11 May 2017 Charles B O'keeffe
Director
Option 31,250 $1.04 $32,500
11 May 2017
463,376
12 Jul 2016 Charles B O'keeffe
Director
Buy 20,000 $0.81 $16,200
12 Jul 2016
432,126
26 Apr 2016 Charles B O'keeffe
Director
Buy 20,000 $0.60 $12,000
26 Apr 2016
412,126
26 Apr 2016 Charles B O'keeffe
Director
Buy 20,000 $0.60 $12,000
26 Apr 2016
412,126
16 Mar 2016 Charles B O'keeffe
Director
Buy 10,000 $1.11 $11,100
16 Mar 2016
392,126
16 Mar 2016 Charles B O'keeffe
Director
Buy 10,000 $1.11 $11,100
16 Mar 2016
392,126
1 Feb 2016 Charles B O'keeffe
Director
Buy 5,000 $1.87 $9,350
1 Feb 2016
382,126
1 Feb 2016 Charles B O'keeffe
Director
Buy 5,000 $1.87 $9,350
1 Feb 2016
382,126
8 Jan 2016 Charles B O'keeffe
Director
Buy 5,000 $1.94 $9,700
8 Jan 2016
377,126
8 Jan 2016 Charles B O'keeffe
Director
Buy 5,000 $1.94 $9,700
8 Jan 2016
377,126
23 Dec 2015 Charles B O'keeffe
Director
Buy 5,000 $2.41 $12,050
23 Dec 2015
372,126
23 Dec 2015 Charles B O'keeffe
Director
Buy 5,000 $2.41 $12,050
23 Dec 2015
372,126
19 Nov 2015 Charles B O'keeffe
Director
Buy 5,000 $2.30 $11,500
19 Nov 2015
367,126
19 Nov 2015 Charles B O'keeffe
Director
Buy 5,000 $2.30 $11,500
19 Nov 2015
367,126
1 Oct 2015 Charles B O'keeffe
Director
Buy 10,000 $2.85 $28,500
1 Oct 2015
362,126
25 Aug 2015 Charles B O'keeffe
Director
Option 30,000 $1.09 $32,700
25 Aug 2015
352,126
30 Apr 2015 Charles B O'keeffe
Director
Buy 10,000 $3.29 $32,900
30 Apr 2015
322,126
24 Apr 2015 Charles B O'keeffe
Director
Buy 5,000 $3.80 $19,000
24 Apr 2015
312,126
13 Jan 2015 Charles B O'keeffe
Director
Buy 10,000 $3.00 $30,000
13 Jan 2015
307,126
2 Oct 2014 Charles B O'keeffe
Director
Option 105,000 $0.90 $94,500
2 Oct 2014
297,126
19 May 2014 Charles B O'keeffe
Director
Buy 10,000 $1.83 $18,300
19 May 2014
192,126
16 Apr 2014 Charles B O'keeffe
Director
Buy 5,000 $2.02 $10,100
16 Apr 2014
182,126
5 Feb 2014 Charles B O'keeffe
Director
Buy 10,000 $1.81 $18,100
5 Feb 2014
177,126
21 Oct 2013 Charles B O'keeffe
Director
Buy 10,000 $1.84 $18,400
21 Oct 2013
167,126
15 Nov 2012 Charles B O'keeffe
Director
Buy 25,000 $0.42 $10,500
15 Nov 2012
157,126
1 Jun 2012 Charles B O'keeffe
Director
Buy 20,000 $0.57 $11,400
1 Jun 2012
132,126
24 May 2012 Charles B O'keeffe
Director
Buy 31,250 $0.80 $25,000
24 May 2012
112,126
17 Jun 2010 Charles B O'keeffe
Director
Buy 2,000 $1.05 $2,100
17 Jun 2010
80,876
18 Mar 2010 Charles B O'keeffe
Director
Buy 5,000 $0.72 $3,600
18 Mar 2010
78,876
17 Nov 2009 Charles B O'keeffe
Director
Buy 10,000 $0.73 $7,300
17 Nov 2009
73,876
30 Oct 2008 Charles B O'keeffe
Director
Buy 5,100 $2.21 $11,271
30 Oct 2008
63,876
24 Jan 2008 Charles B O'keeffe
Director
Buy 5,000 $3.05 $15,250
24 Jan 2008
58,776
16 Nov 2007 Charles B O'keeffe
Director
Buy 5,000 $2.50 $12,500
16 Nov 2007
53,776
1 Nov 2007 Charles B O'keeffe
Director
Buy 4,924 $3.00 $14,772
1 Nov 2007
48,776
29 Aug 2007 Charles B O'keeffe
Director
Buy 76 $2.75 $209
29 Aug 2007
43,852


Catalyst Pharmaceuticals Inc executives and stock owners

Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include: